MacroGenics Inc (MGNX) - Net Assets
Based on the latest financial reports, MacroGenics Inc (MGNX) has net assets worth $55.59 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($256.85 Million) and total liabilities ($201.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MacroGenics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $55.59 Million |
| % of Total Assets | 21.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -76.8% |
| 10-Year Change | -79.32% |
| Growth Volatility | 53.41 |
MacroGenics Inc - Net Assets Trend (2011–2025)
This chart illustrates how MacroGenics Inc's net assets have evolved over time, based on quarterly financial data. Also explore MacroGenics Inc (MGNX) total assets for the complete picture of this company's asset base.
Annual Net Assets for MacroGenics Inc (2011–2025)
The table below shows the annual net assets of MacroGenics Inc from 2011 to 2025. For live valuation and market cap data, see MGNX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $55.59 Million | -52.10% |
| 2024-12-31 | $116.06 Million | -23.95% |
| 2023-12-31 | $152.61 Million | +7.46% |
| 2022-12-31 | $142.01 Million | -40.73% |
| 2021-12-31 | $239.62 Million | -19.02% |
| 2020-12-31 | $295.88 Million | +28.29% |
| 2019-12-31 | $230.63 Million | -5.04% |
| 2018-12-31 | $242.88 Million | -18.83% |
| 2017-12-31 | $299.24 Million | +11.34% |
| 2016-12-31 | $268.75 Million | -14.23% |
| 2015-12-31 | $313.34 Million | +158.35% |
| 2014-12-31 | $121.29 Million | +53.69% |
| 2013-12-31 | $78.91 Million | +1058.01% |
| 2012-12-31 | $-8.24 Million | +52.89% |
| 2011-12-31 | $-17.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MacroGenics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 106050384200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $633.00K | 1.14% |
| Other Comprehensive Income | $32.00K | 0.06% |
| Other Components | $1.30 Billion | 2337.18% |
| Total Equity | $55.59 Million | 100.00% |
MacroGenics Inc Competitors by Market Cap
The table below lists competitors of MacroGenics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gwangjushinseg
KO:037710
|
$199.00 Million |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
$199.00 Million |
|
Sif Holding NV
AS:SIFG
|
$199.06 Million |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
$199.16 Million |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
$198.85 Million |
|
Pyridam Farma Tbk
JK:PYFA
|
$198.84 Million |
|
PAMT CORP
NASDAQ:PAMT
|
$198.76 Million |
|
Siward Crystal Technology Co Ltd
TW:2484
|
$198.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MacroGenics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 116,057,000 to 55,591,000, a change of -60,466,000 (-52.1%).
- Net loss of 74,620,000 reduced equity.
- Other comprehensive income increased equity by 28,000.
- Other factors increased equity by 14,126,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.62 Million | -134.23% |
| Other Comprehensive Income | $28.00K | +0.05% |
| Other Changes | $14.13 Million | +25.41% |
| Total Change | $- | -52.10% |
Book Value vs Market Value Analysis
This analysis compares MacroGenics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.96 | $3.13 | x |
| 2012-12-31 | $-0.45 | $3.13 | x |
| 2013-12-31 | $3.00 | $3.13 | x |
| 2014-12-31 | $4.43 | $3.13 | x |
| 2015-12-31 | $9.85 | $3.13 | x |
| 2016-12-31 | $7.75 | $3.13 | x |
| 2017-12-31 | $8.29 | $3.13 | x |
| 2018-12-31 | $5.93 | $3.13 | x |
| 2019-12-31 | $4.80 | $3.13 | x |
| 2020-12-31 | $5.64 | $3.13 | x |
| 2021-12-31 | $4.00 | $3.13 | x |
| 2022-12-31 | $2.31 | $3.13 | x |
| 2023-12-31 | $2.46 | $3.13 | x |
| 2024-12-31 | $1.85 | $3.13 | x |
| 2025-12-31 | $0.88 | $3.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MacroGenics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -134.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.91%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 4.62x
- Recent ROE (-134.23%) is below the historical average (-40.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 14.28% | 0.75x | 0.00x | $8.47 Million |
| 2012 | 0.00% | 14.02% | 1.11x | 0.00x | $9.19 Million |
| 2013 | -0.33% | -0.46% | 0.45x | 1.59x | $-8.15 Million |
| 2014 | -31.59% | -81.06% | 0.27x | 1.43x | $-50.44 Million |
| 2015 | -6.43% | -19.97% | 0.28x | 1.15x | $-51.47 Million |
| 2016 | -21.78% | -67.60% | 0.28x | 1.16x | $-85.40 Million |
| 2017 | -6.56% | -12.62% | 0.42x | 1.25x | $-49.55 Million |
| 2018 | -70.59% | -285.18% | 0.18x | 1.37x | $-195.74 Million |
| 2019 | -65.83% | -244.76% | 0.20x | 1.36x | $-174.87 Million |
| 2020 | -39.81% | -120.48% | 0.26x | 1.28x | $-147.37 Million |
| 2021 | -79.65% | -252.31% | 0.23x | 1.40x | $-214.82 Million |
| 2022 | -84.51% | -78.99% | 0.52x | 2.04x | $-134.22 Million |
| 2023 | -5.94% | -15.84% | 0.19x | 1.96x | $-24.32 Million |
| 2024 | -57.70% | -45.14% | 0.57x | 2.25x | $-78.57 Million |
| 2025 | -134.23% | -49.91% | 0.58x | 4.62x | $-80.18 Million |
Industry Comparison
This section compares MacroGenics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MacroGenics Inc (MGNX) | $55.59 Million | 0.00% | 3.62x | $198.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more